Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.
Morningstar7d
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
It is designed to provide women with a long-acting ... commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil, the active ...
Investing21d
Dare Bioscience secures additional NIAID funding for HPV treatment
In other recent news, Daré Bioscience, Inc. has made significant strides in the women's health sector. The company plans to initiate a Phase 3 clinical trial for Sildenafil Cream, a possible ...
Investing21d
Dare Bioscience secures additional NIAID funding for HPV treatment
In other recent news, Daré Bioscience, Inc. has made significant strides in the women's health sector. The company plans to initiate a Phase 3 clinical trial for Sildenafil Cream, a possible ...
FiercePharma6d
Cosette sets sights on women's healthcare stardom with $430M Mayne Pharma buy
With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...
Investing7d
Daré, Theramex partner on biodegradable contraceptive implant
SAN DIEGO - Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focusing on women's health with a market capitalization ... Daré Bioscience is set to initiate a Phase 3 clinical trial ...
Dare Bioscience risks Nasdaq delisting over market value
SAN DIEGO, CA – Daré Bioscience, Inc., a biopharmaceutical company with a current market capitalization of $26.45 million and trading at $3.04 per share, is facing potential delisting from the Nasdaq ...